Introduction {#Sec1}
============

Antisense oligonucleotides (ASOs) are highly selective therapeutics that have demonstrated broad in vitro and in vivo activities and produced clinical benefit based upon a concept originally proposed in 1978 \[[@CR1]\]. These drugs are short (12--20-mer) nucleic acid sequences that bind, via Watson--Crick hybridization, to their complementary RNA substrates, which are their receptors. Upon hybridization, ASOs inactivate RNA via two predominant termination mechanisms: (1) occupancy only, in which the binding of the ASO leads to translational arrest, inhibition of splicing, or induction of alternatively spliced variants, or (2) occupancy-induced destabilization, in which the RNA/DNA duplex is recognized and degraded by ribonuclease H1 (RNase H1), a ubiquitously expressed cellular endonuclease \[[@CR2]\]. ASOs employing the RNase H pathway are widely used in the clinical setting, and this destabilization mechanism is utilized by all of the ASOs featured in this review.

The evolution of antisense technology from a simple cell-free experiment to a bona fide therapeutic platform was not trivial. For example, unmodified phosphodiester DNA ASOs had little therapeutic benefit due to their short half-lives, poor tissue distribution, and low affinity for RNA targets. Therefore, one of the initial steps that led to significant improvements in the pharmacology of ASOs was the replacement of the native phosphates in the backbone, which are highly sensitive to plasma and tissue exo- and endonucleases, with phosphorothioates (PSs) \[[@CR3]\]. While the PS modification significantly improved stability and tissue distribution by enhancing plasma protein binding and prolonging tissue half-lives (1--3 days), the addition of the sulfur also tended to increase ASO pro-inflammatory properties. Second-generation ASOs involved altering the sugar moiety (see Fig. [1](#Fig1){ref-type="fig"}), with the most well characterized incorporating a methoxyethyl to the 2′ position (2′-MOE) or, alternatively, by tethering of the 4′-carbon to the 2′-hydroxyl of the ribose ring to create the bicyclic locked nucleic acid (LNA). These changes increased the melting temperatures of the RNA/ASO duplexes by 2--5 °C/modification and resulted in an increased affinity for the RNA substrate \[[@CR2], [@CR4], [@CR5]\]. In addition, the proximity of the 2′ modification to the 3′-phosphate likely created a steric hindrance that improved nuclease resistance \[[@CR6]\] and altered non-specific protein binding, thus markedly reducing the pro-inflammatory properties of the ASOs \[[@CR7]\]. Unfortunately, when added uniformly, both sugar modifications also made the ASO/RNA target duplex a poor substrate for the RNase H enzyme. To circumvent this, a "gapmer" design was implemented (see Fig. [1](#Fig1){ref-type="fig"}), in which the flanking regions of the ASO contain the 2′-MOE or LNA modifications while the center of the compound maintains unmodified sugars that serve as suitable substrates for RNase H-mediated cleavage \[[@CR8]\].Fig. 1Overview of ASO modifications. **a** Chemical structure of the 2′4′-locked nucleic acid (*LNA*) and the 2′-*O*-methoxyethyl RNA (*MOE*). **b** Schematic of the gapmer ASO design. In order to facilitate RNase H activity, unmodified DNA is included in the internal, typically ten, nucleotides ("the gap"). The gap is flanked on the 5′ and 3′ ends with two to five of the MOE/LNA-modified nucleotides, which enhances ASO stability and affinity for the target RNA

With the enhanced stability, increase in potency, and reductions in non-specific toxicities, second-generation ASOs (2′-MOE gapmers) have been widely used in vivo. Since these drugs are readily soluble in saline, they can be administered without special formulation by multiple routes (subcutaneous, intravenous, intravitreal, topical, aerosol, oral, or enema) \[[@CR9]\]. Tissue distribution of parenterally administered ASOs, which has been characterized extensively in preclinical models, is predominantly within the liver, kidney, and spleen with lesser distribution observed in the heart, ovaries, pancreas, testes, and uterus \[[@CR10], [@CR11]\]. ASOs accumulate in cells through either a non-productive pathway, resulting in accumulation of drug into lysosomes, or a productive, endocytotic process whereby the drug gains access to the target mRNA \[[@CR9]\]. Tissue half-lives of 2′-MOE gapmers range from 10 to 30 days, and typically, reductions in mRNA and protein in animal models can be observed as early as 24--48 h after initial dosing, with maximal efficacy occurring after 1 month of repeated administration \[[@CR12]\]. In general, second-generation drugs have an attractive safety profile, both preclinically and in the clinic. The most commonly reported adverse events are transient injection site reactions, which are characterized by mild to moderate erythema, and flu-like symptoms \[[@CR13]\].

Small interfering RNA (siRNA) represents another antisense mechanism used to reduce target mRNA expression \[[@CR14]\]. SiRNAs are delivered as a duplex to the RNA-induced silencing complex (RISC), which contains several proteins including Argonaute 2 (Ago2), another cellular endonuclease. Ago2 cleaves the siRNA duplex into a guide and a passenger strand, while the RISC complex retains the guide strand and releases the passenger strand \[[@CR15]\]. The RISC/guide strand forms a haloenzyme which can then bind its single-strand mRNA complement and cleave via an Ago2-mediated process \[[@CR16]\]. Due to their inherent chemical properties, siRNAs must be formulated with lipid conjugates or nanoparticles for effective in vivo drug delivery \[[@CR17]\].

Finally, another antisense approach uses the microRNA (miRNA) pathway. MiRNAs are endogenous non-coding RNAs, approximately 22 nucleotides in length, that post-transcriptionally regulate numerous cellular and metabolic pathways \[[@CR18]\]. Two strategies have evolved to alter miRNA activity, the first using synthetic mimicry of naturally occurring miRNAs, while the second blocks activity via complementary ASO inhibitors \[[@CR19]\]. However, this relatively new antisense approach is still in preclinical development and will not be discussed in this review.

ASOs have been successfully used for a variety of disease states, including cancer \[[@CR20]--[@CR22]\], viral infection \[[@CR23]\], insulin resistance \[[@CR24], [@CR25]\], neurological/neuromuscular diseases \[[@CR26], [@CR27]\], inflammatory diseases \[[@CR7]\], and ocular diseases \[[@CR28], [@CR29]\]. However, this review will primarily focus on the clinical successes of ASOs in cardiovascular disease.

Kynamro {#Sec2}
=======

The most advanced antisense drug is mipomersen sodium (trade name Kynamro, Table [1](#Tab1){ref-type="table"}), a second-generation 2′-MOE gapmer ASO that targets the messenger RNA (mRNA) of apolipoprotein B (apoB) \[[@CR30]\]. ApoB is the main structural component of the atherogenic lipoproteins VLDL, IDL, and LDL, collectively referred to as non-high-density lipoprotein (non-HDL). It is well established that plasma apoB, LDL cholesterol (LDL-C), and non-HDL cholesterol (non-HDL-C) are positively associated with coronary heart disease \[[@CR31]\]. While the HMG-CoA reductase small molecule inhibitors (statins) have proven to be invaluable drugs for lowering LDL-C in the general population, there are still a significant number of patients at high risk for a cardiovascular event due, in part to, the inability to achieve their target LDL-C concentrations \[[@CR32]\]. Familial hypercholesterolemic (FH) patients are at greatest risk, due to mutations in their LDL receptor which render them unable to clear plasma apoB-containing lipoproteins, resulting in markedly elevated plasma non-HDL-C concentrations and early onset of coronary heart disease (CHD) \[[@CR33]\]. Because raising LDL receptor levels is the primary mechanism by which statins reduce circulating LDL-C, the efficacy of these drugs in the FH patient population has been limited \[[@CR34]\]. Therefore, apoB represents an attractive molecular target for the antisense technology as (1) it is primarily expressed in the liver and (2) it does not possess enzymatic activity, making it "undruggable" by traditional small molecule inhibitors. In addition, since mipomersen inhibits apoB lipoprotein particle production and not LDL receptor clearance, it was initially hypothesized that administration of the drug would be useful in treating the high-risk FH patient population. Based upon these attributes, as well as positive clinical efficacy data, acceptable safety, and tolerability in preclinical models and in patients, the development of mipomersen by Isis Pharmaceuticals and Genzyme, a Sanofi Company, ultimately led to FDA approval for its use as an adjunct to lipid-lowering medications and diet to reduce LDL-C, apoB, total cholesterol, and non-HDL-C in patients with homozygous FH \[[@CR35]\].Table 1Summary of antisense drugs approved or in clinical trialsDrug nameDrug targetCardiovascular effectCurrent statusKynamroApolipoprotein BLowers plasma apoB, TPC, LDL-C, non-HDL-C, and Lp(a)FDA approval for its use as an adjunct to lipid-lowering medications for homozygous FH patientsSPC4955Apolipoprotein BLowers plasma apoB, TPC, LDL-C, non-HDL-C, and Lp(a)Phase I (completed)ApoC-III~Rx~Apolipoprotein C-IIILowers plasma apoC-III and TGPhase I (completed), Phase II initiatedFXI~Rx~Factor XIPrevents thrombosisPhase I (completed)BMS-844421PCSK9Lowers plasma apoB, TPC, LDL-C, and non-HDL-CPhase I (terminated)SPC5001PCSK9Lowers plasma apoB, TPC, LDL-C, and non-HDL-CPhase I (terminated)ALN-PCS02PCSK9Lowers plasma apoB, TPC, LDL-C, and non-HDL-CPhase I (completed)ApoA~Rx~Apolipoprotein(a)Lowers Lp(a)Phase I initiated*TPC* total plasma cholesterol

In preclinical studies, mice administered a murine apoB ASO produced dose-dependent reductions in hepatic apoB mRNA and protein, and concurrent reductions in plasma apoB, cholesterol, and LDL-C \[[@CR36]\]. Subsequent studies in low-density lipoprotein receptor (LDLR) −/− mice demonstrated expected suppression of atherogenic lipoproteins with concomitant dose-dependent reductions in aortic atherosclerosis \[[@CR37]\]. Interestingly, despite reducing VLDL secretion, an event that could potentially lead to hepatic triglyceride (TG) accumulation, chronic administration of the murine apoB ASO did not produce such changes \[[@CR36]--[@CR38]\]. While the precise underlying mechanisms are still under investigation, it was shown in part to be due to the up-regulation of fatty acid oxidation and down-regulation of lipogenic genes such as sterol response element binding protein 1-c (SREBP1-c), acetyl-CoA carboxylase 1, and hepatic fatty acid synthase (FASN) with a tendency to suppress hepatic fatty acid synthesis. This observation was also made in mice harboring the apoB 38.9 truncation \[[@CR39]\]. Further preclinical studies demonstrated that, much like mice, administration of the apoB ASO to rats, hamsters, rabbits, and monkeys led to reductions in hepatic apoB mRNA and protein, and concomitant reduction in plasma apoB, cholesterol, and LDL-C \[[@CR30]\]. In addition, transcriptional profiling of livers from monkeys administered a monkey apoB ASO demonstrated similar reductions in lipogenic genes such as SREBP1-c and FASN. Consistent with these compensatory effects, the monkeys, like the mice, did not develop hepatic steatosis.

In the first short-term placebo-controlled, double-blind, dose-escalation Phase I trial \[[@CR40]\], subcutaneous (SC) administration of mipomersen to healthy volunteers was efficacious. Dose-dependent reductions occurred in both apoB and LDL-C levels relative to baseline, with the 200-mg dose of mipomersen producing a maximum apoB reduction of 50 % and a maximum LDL-C reduction of 35 %. The observed pharmacology correlated with drug exposure as estimated by the area under the curve for drug plasma trough levels. In subjects who received the 200-mg dose, the drug's terminal elimination half-life was approximately 30 days. This durability was reflected by prolonged pharmacology, where apoB and LDL-C levels remained below baseline for 3 months after treatment in most subjects (six of eight) of the 200 mg dose group. No significant changes occurred in HDL-C levels across all dose groups.

In a second Phase I trial designed to evaluate clinical pharmacokinetics, mipomersen was coadministered with either simvastatin, an HMG-CoA reductase inhibitor, or ezetimibe, a drug that blocks cholesterol absorption \[[@CR41]\]. The results from this study demonstrated no clinically relevant pharmacokinetic interactions between mipomersen and the other dyslipidemia agents. Further to these results, in vitro assays demonstrated no effect of mipomersen on cytochrome P450 activity or P-glycoprotein.

Several short-term randomized, placebo-controlled, dose-escalation Phase II trials were performed where mipomersen was evaluated as a single agent \[[@CR42]\] and as an add-on to stable lipid-lowering therapy \[[@CR43], [@CR44]\] in subjects with varying degrees of hyperlipidemia. As a monotherapy, mipomersen produced reductions from baseline of −7 to −71 % in LDL-C after 13 weeks of dosing at 50 to 400 mg/week, respectively. A large proportion of subjects who received ≥200 mg/week mipomersen (19 of 24) achieved LDL-C levels below 2.6 mmol/L (100 mg/dL), where the mean baseline level of mipomersen-treated subjects was 4.5 mmol/L (170 mg/dL). Parallel dose-dependent reductions occurred in apoB and non-HDL-C. Indeed, half of the subjects who received the highest dose of 400 mg/week mipomersen achieved apoB levels at or below the limit of detection of 35 g/L by week 12.

A similar profile was observed when mipomersen treatment was added to ongoing stable statin therapy \[[@CR43]\]. In a 5-week dose-escalation Phase II study, subjects who received the 200-mg dose of mipomersen had a significant mean reduction in LDL-C of −27 % from baseline while the 400-mg dose resulted to a mean reduction of −38 %. Parallel reductions occurred in apoB and non-HDL-C. In a separate cohort, administration of mipomersen (200 mg) weekly led to 36 % reduction in both apoB and LDL-C from baseline after 13 weeks of treatment.

A third dose-escalation Phase II trial involved subjects diagnosed with heterozygous FH on stable lipid-lowering therapy who received 50 to 300 mg/week mipomersen, or placebo, over a 6-week treatment period \[[@CR44]\]. In this study population, LDL-C was significantly reduced from baseline compared to pooled placebo in the 200 and 300 mg/week dose groups by −21 and −34 %, respectively, with concordant dose-dependent reductions in apoB, non-HDL-C, and total cholesterol. Subjects assigned to the 300 mg/week cohort continued once-weekly dosing for an additional 7 weeks to achieve a mean reduction of −37 % in LDL-C and apoB from baseline, 1 week after the last dose.

Overall, mipomersen was well tolerated in each of the three short-term Phase II trials. The most common adverse event reported was injection site reactions (ISRs), a common side effect of subcutaneously administered drugs \[[@CR45]--[@CR47]\]. Elevations in liver transaminases, which were reversible upon continued dosing or once the drug was discontinued, occurred in a limited number of subjects treated with mipomersen at doses of 200 mg or higher. These elevations were asymptomatic and not accompanied by abnormalities in other measures of liver function, such as total bilirubin, albumin, and prothrombin. There were no clinically relevant changes or treatment effects in other safety and laboratory assessments, such as vital signs, electrocardiograms, renal function tests, coagulation, and urinalyses.

Three 26-week randomized, placebo-controlled Phase III trials that enrolled FH patients with a range of risk and severity of cardiovascular disease were also conducted \[[@CR48]--[@CR50]\]. The first trial evaluated the effects of mipomersen in patients with the most severe form of this genetic disease, homozygous FH \[[@CR48]\]. Homozygous FH patients on stable low-fat diets and maximally tolerated lipid-lowering therapy (LLT) were administered once-weekly SC doses of either mipomersen (200 mg) (*n* = 34) or placebo (*n* = 17) for 26 weeks. Dose adjustments were not permitted. The mean age was 31 years, and 44 of 51 patients (86 %) were taking the maximum dose of a statin or other LLT. Two weeks following the final dose, patients who received mipomersen showed a significant mean reduction in plasma LDL-C (−25 vs. −3 % placebo, *p* = 0.0003) from a mean baseline level of 11.4 mmol/L (440 mg/dL). This response corresponded to a mean absolute reduction of −2.9 mmol/L (−113 mg/dL) in LDL-C. Furthermore, plasma apoB levels decreased by a significant amount relative to baseline (−27 vs. −3 % placebo, *p* \< 0.0001). Notably, a significant increase in HDL-C levels from baseline occurred in mipomersen-treated patients (+15 vs. +4 % placebo, *p* = 0.03).

The second Phase III trial involved heterozygous FH patients with stable coronary artery disease \[[@CR49]\]. Patients were administered either mipomersen (200 mg) (*n* = 83) or placebo (*n* = 41) once weekly (SC administration) for 26 weeks as an add-on to ongoing maximum tolerated dose of a statin and stable LLT. The mean age was 56 years, and 81 of 124 patients (65 %) were taking the maximum dose of a statin. Two weeks following the final dose, patients who received mipomersen experienced a significant reduction in plasma LDL-C (−28 vs. +5.2 % placebo, *p* \< 0.001) from a mean baseline level of 4.0 mmol/L (153 mg/dL). This response corresponded to a mean absolute reduction of −1.3 mmol/L (−49 mg/dL) in LDL-C. ApoB also decreased by a significant amount relative to baseline (−26 vs. +7 % placebo, *p* \< 0.001), as did other apoB-containing lipoproteins such as non-HDL-C and lipoprotein (a) (Lp(a)). Assessment of liver TG content by magnetic resonance imaging at baseline and end of treatment showed a median increase in liver fat content of +4.9 % in mipomersen-treated patients, compared to +0.4 % in placebo.

The third Phase III trial evaluated mipomersen in patients with severe hypercholesterolemia (HC). Severe HC was defined as LDL-C greater than or equal to 7.8 mmol/L (300 mg/dL), or LDL-C ≥ 5.1 mmol/L (200 mg/dL) with pre-existing CHD, while on a maximum tolerated statin dose and stable LLT \[[@CR50]\]. Patients were administered once-weekly SC doses of either mipomersen (200 mg) (*n* = 39) or placebo (*n* = 19) for 26 weeks as an add-on to ongoing therapy. The mean age was 51 years, and 24 of 58 patients (41 %) were taking a maximum statin dose. Two weeks following the final dose, patients who received mipomersen experienced a significant reduction in plasma LDL-C (−36 vs. +13 % placebo, *p* \< 0.001) from a mean baseline level of 7.2 mmol/L (276 mg/dL). This response corresponded to a mean absolute reduction of −2.6 mmol/L (−101 mg/dL) in LDL-C. ApoB decreased to a similar extent relative to baseline (−36 vs. +11 % placebo, *p* \< 0.001).

Mipomersen has also been evaluated for safety and efficacy in two other high-risk CHD populations based on the same study design as the aforementioned Phase III trials \[[@CR51], [@CR52]\]. One was a Phase III trial that involved patients at high risk for CHD and with LDL-C levels greater than or equal to 2.6 mmol/L (100 mg/dL) despite treatment with a maximum tolerated statin dose and LLT \[[@CR52]\]. In this study, 88 of 153 randomized patients (56 %) were type 2 diabetics. The other 26-week placebo-controlled trial involved subjects with uncontrolled LDL-C levels (≥3.4 mmol/L) who were intolerant to statins \[[@CR51]\]. Nearly half of the subjects (15 of 33) in this study were not taking lipid-lowering medications. Mipomersen produced robust reductions in LDL-C from baseline compared to placebo in both study populations, with a mean percentage change from baseline of −37 % (vs. −5 % placebo, *p* \< 0.001) and −47 % (vs. −2 % placebo, *p* \< 0.001) 2 weeks after the last dose, respectively. Concordant reductions occurred in all apoB-containing lipoproteins tested, including non-HDL-C and Lp(a).

No new safety concerns emerged in the Phase III trials. Consistent with previous studies, the most common side effects experienced by patients were ISRs and flu-like symptoms. A limited number of patients also experienced persistent elevations in liver transaminase levels. These increases were not accompanied by abnormalities in other measures of liver function, were largely reversible with continued treatment or otherwise, and receded back to baseline values in post-dose follow-up. Beyond these findings, no additional safety issues have been identified in the corresponding Phase III open-label extension trial \[[@CR53]\]. Notably, increases in liver fat content have tended to stabilize or decrease after 1 year of treatment in patients participating in the Phase III extension. This trend may reflect compensatory changes in hepatic lipid metabolism first observed in the preclinical animal model studies.

As described above, mipomersen has been approved by the FDA for use as an adjunct to first-line therapies in homozygous FH patients to reduce LDL-C, non-HDL-C, apoB, and total cholesterol. Another randomized, double-blind, placebo-controlled Phase III trial is currently in progress to assess the safety and efficacy of an alternative lower and more frequent dose regimen and the approved 200-mg weekly dose regimen in patients with severe FH \[[@CR6]\]. The estimated study completion date is late 2014. Positive safety and efficacy data will further support consideration of mipomersen for use as an adjunct to existing therapies in other high-risk patient populations.

In addition to mipomersen, both siRNA and LNA oligonucleotides targeting apoB mRNA have been studied \[[@CR54], [@CR55]\]. Currently, the siRNA has only been evaluated in rodents and non-human primates, but at the time of this publication had not advanced into clinical trials. A multiple-ascending-dose Phase I clinical trial in 18 healthy subjects with the apoB LNA (SPC4955) was completed in November 2011, but at present, the outcome of the trial has not been disclosed \[[@CR56]\], nor have any other clinical trials been initiated.

ISIS-APOCIII~Rx~ {#Sec3}
================

Hypertriglyceridemia (HTG) is an independent risk factor for cardiovascular disease \[[@CR57]\] and pancreatitis \[[@CR58], [@CR59]\]. Furthermore, it has been shown that reducing plasma TG below 5.7 mmol/L (500 mg/dL) in severe HTG patients had both clinical and economic benefits \[[@CR60]\].

Apolipoprotein C-III (apoC-III) is an important regulatory factor in plasma TG homeostasis. It is a 79-amino acid glycoprotein that is present on all lipoprotein classes, with the majority found on HDL particles (60 % of total plasma apoC-III) and less on the apoB-containing lipoprotein particles (20, 10, and 10 % of total plasma \[[@CR61]\] apoC-III is found on VLDL, IDL, and LDL, respectively) \[[@CR62]\]. Studies in animal models and humans indicate that apoC-III affects plasma TG catabolism. In mice, over-expression of apoC-III leads to marked HTG \[[@CR63], [@CR64]\], while genetic knockout results in reductions in plasma TG \[[@CR65], [@CR66]\]. The importance of apoC-III was highlighted in an Old World Amish population where a heterozygous loss-of-function allele for *APOC3* resulted in significantly reduced plasma TG and LDL-C, as well as increased HDL-C \[[@CR67]\]. In contrast, it was found that gain-of-function mutations in the *APOC3* promoter in an Asian Indian population led to significantly increased fasting plasma TG levels \[[@CR68]\]. While the exact mechanism by which apoC-III exerts its effects is unclear, there is evidence that it may act directly by inhibiting lipoprotein lipase \[[@CR69]\], reducing clearance of TG-rich lipoproteins \[[@CR70]\], and enhancing hepatic TG secretion \[[@CR71]\]. However, the relative contribution of each of these pathways is uncertain.

Analysis of the Cholesterol and Recurrent Events trial showed that in a model which adjusted for LDL-C, VLDL-C, TG, and HDL-C, apoC-III VLDL + LDL remained an independent risk factor for a recurrent event \[[@CR72]\], indicating that the pro-atherogenic properties of apoC-III extend beyond its role in TG metabolism. Subsequent studies have shown that apoC-III found on apoB-containing particles has pro-inflammatory properties via enhancing adhesion of monocytic cells to endothelial cells \[[@CR73]\] and downstream induction of endothelial cell vascular cell adhesion molecule I \[[@CR74]\].

In addition to its pro-atherogenic effects, elevated plasma apoC-III concentrations have also been implicated in the development of insulin resistance and diabetes in both preclinical and human epidemiology studies. ApoC-III protein expression has been shown to be regulated by insulin \[[@CR75]\] via a Foxo1-mediated process \[[@CR76]\]. Indeed, dietary-challenged transgenic mice over-expressing human *APOC3* had significantly elevated insulin levels with no difference in glucose, indicating insulin resistance \[[@CR64]\]. In humans, variants in an insulin response element of the *APOC3* promoter led to loss of insulin-mediated apoC-III transcriptional regulation. This was later associated with an increased incidence of NAFLD and insulin resistance in an Asian Indian population \[[@CR68]\]. However, this result was not replicated in a second study performed in an African--American population \[[@CR77]\]. It is also interesting to note that a group of Ashkenazi Jews harboring a loss-of-function mutation in *APOC3* that only lowered plasma apoC-III protein by 30 % did not significantly change plasma TG, but remained associated with improved insulin sensitivity, lower blood pressure, and increased longevity \[[@CR78]\], further suggesting the involvement of apoC-III in multiple, complex metabolic pathways.

Due to the large body of evidence summarized above implicating apoC-III in cardiovascular and metabolic disease progression, apoC-III ASOs were developed targeting mouse, rat, monkey, and human transcripts \[[@CR79]\]. In several mouse and rodent models, administration of apoC-III ASO led to significant dose-dependent reductions in apoC-III and concomitant significant reductions in plasma TG. Administration of apoC-III ASO to *apoC3* −/− mice had no effect on plasma TG, indicating that the TG-lowering effects of the apoC-III ASO were target specific. Hepatic TG secretion in apoC-III ASO-treated C57BL/6 mice receiving poloxamer 407, which blocks apoB particle clearance allowing for quantitation of apoB secretion \[[@CR80]\], was not different compared to that in controls, suggesting that the TG-lowering effects of the apoC-III ASO were due to changes in clearance, not hepatic secretion. Administration of apoC-III ASO to HTG rhesus monkeys also led to significant dose-dependent reductions in plasma apoC-III mRNA with subsequent reduction in plasma TG.

Due to significant and consistent TG-lowering effects in multiple preclinical species with no apparent tolerability issues, a Phase I clinical trial of the human apoC-III ASO (ISIS-APOCIII~Rx~-ISIS 308401), a 5--10--5 MOE gapmer, was initiated. This double-blind, placebo-controlled, dose-escalation study, in which patients were dosed for 4 weeks with 50, 100, 200, or 400 mg of ISIS-APOCIII~Rx~, was performed in healthy human volunteers to assess safety, pharmacokinetics, and pharmacodynamics \[[@CR79]\]. As observed in preclinical studies, administration of ISIS 308401 led to significant dose-dependent reductions in apoC-III protein with concomitant reductions in plasma TG (−50 %) relative to baseline at the highest administered dose. Reductions in plasma apoC-III protein and TG were seen as early as 8 days after the initial dose \[[@CR79]\]. ISIS 308401 was generally well tolerated with no serious adverse events or early dosing terminations. Consistent with administration of other second-generation antisense drugs, the most common adverse events were ISRs. The successful completion of this Phase I trial in healthy human volunteers has since led to Phase II trials in subjects with very high TG levels \[[@CR61]\] and those with moderately high TG levels and type 2 diabetes \[[@CR81]\].

ISIS-FXI~Rx~ {#Sec4}
============

Precise control of the coagulation cascade at sites of vessel wall injury leads to thrombin production and the formation of a hemostatic plug. Patients with low levels of coagulation factor XI (FXI) have a reduced risk for thromboembolic diseases \[[@CR37], [@CR38]\] with no associated bleeding issues, demonstrating that FXI appears to play only a minor role in hemostasis \[[@CR82], [@CR83]\]. Increased FXI levels in patients may result in increased risk of venous thrombosis, myocardial infarction, and stroke \[[@CR84], [@CR85]\]. Further, several preclinical studies demonstrating the importance of FXI in thrombosis \[[@CR86]--[@CR91]\], with minimal contribution to hemostasis, validate FXI as an attractive pharmacological target.

To further characterize the role of coagulation factors in thrombosis, mouse-specific ASOs were developed to specifically deplete the expression of individual coagulation factors. Mouse studies utilizing FXI-specific ASOs demonstrated that inhibition of FXI mRNA in the liver led to reduced levels of plasma FXI protein and activity \[[@CR92]\]. The measured anticoagulant effect after ASO depletion of FXI resulted in a dose-dependent prolongation of activated partial thromboplastin time (aPTT) with no effect on prothrombin time. The treatment of mice with FXI ASOs resulted in antithrombotic effects in the FeCl~3~-induced IVC thrombosis model with no increased bleeding. The use of warfarin in that study was effective at reducing thrombosis, but increased bleeding. FXI ASO treatment was also effective at reducing thrombosis in a mesenteric vein and stenosis-induced mouse model without increased bleeding \[[@CR92]\]. To determine the safety and effectiveness of FXI ASOs in combination with standard of care agents, studies were carried out with either an anticoagulant (Lovenox®) or an antiplatelet drug (Plavix®). Results from these experiments demonstrated increased antithrombotic activity without enhancement in bleeding risk \[[@CR92]\].

To evaluate the safety and pharmacodynamic profile of FXI ASOs in primates, the drug was subcutaneously administered for 13 weeks in cynomolgus monkeys \[[@CR93]\]. Those results demonstrated a dose-dependent reduction of FXI mRNA level in the liver and plasma with a corresponding increase in aPTT. The potential for increased bleeding after FXI inhibition was examined in tissues of high fibrinolytic activity using surgical models (oral mucosa and partial tail amputation) in addition to tissues with low intrinsic fibrinolytic activity (skin laceration). A 70 % reduction in plasma FXI activity after FXI ASO treatment resulted in no enhancement in bleeding time or blood volume loss, while enoxaparin treatment increased both endpoint measurements \[[@CR93]\].

Patients with severe FXI deficiency have reduced risk for thrombosis, and baboons treated with a monoclonal antibody (Mab) against FXI, which reduces FXI levels in plasma by 99 %, have reduced thrombosis in a well-characterized baboon model of thrombosis and hemostasis \[[@CR88]\]. Importantly, no increased bleeding was observed with almost complete inhibition of FXI in these monkeys. To define anticoagulation and antithrombotic activity that might ultimately be achieved in clinical applications in humans, the minimal level of FXI reduction in primates required to achieve antithrombotic activity was assessed in a baboon model of thrombosis and hemostasis \[[@CR94]\]. First, the FXI Mab was titrated in these animals to estimate the level of FXI required for antithrombotic activity followed by administration of FXI ASOs until the estimated antithrombotic levels were achieved. An intravenous injection of FXI Mab inhibited both FXI plasma activity and platelet deposition in a propagating thrombus by 50 % \[[@CR94]\]. The FXI ASO was then administered by subcutaneous injection three times per week at a dose of 25 mg/kg, reducing FXI protein and activity levels by 50 % while increasing aPTT. Further, when FXI plasma levels were reduced to less than 50 % of the normal, thrombin generation was almost completely abolished \[[@CR94]\]. Finally, ASO reduction of FXI plasma levels did not increase bleeding in baboons.

The safety, tolerability, and pharmacodynamics of ISIS-FXI~Rx~ were evaluated in a double-blind, ascending-dose, placebo-controlled Phase I study in healthy subjects after a 6-week treatment period. Treatment with ISIS-FXI~Rx~ demonstrated a robust, sustained, and dose-dependent reduction in FXI protein and activity that was accompanied by a concomitant increase in aPTT \[[@CR95]\]. No study drug-related bleeding events were reported even in subjects in whom plasma FXI activity levels were reduced to undetectable levels. ISIS-FXI~Rx~ did not cause clinically significant changes in vital signs, ECG, hepatic function, renal function, or hematology. These data are consistent with preclinical data obtained in multiple species and provide support for development of ISIS-FXI~Rx~ as a novel approach for the treatment and prevention of thromboembolic disorders.

PCSK9 {#Sec5}
=====

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the proprotein convertase family of proteases. Epidemiological studies have suggested that loss-of-function mutations in PCSK9 result in lifelong reductions in LDL-C that are associated with significant reductions in the incidence of coronary heart disease \[[@CR96]--[@CR99]\]. *Pcsk9*-deficient mice exhibited twofold increases in hepatic LDLRs and significant reductions in LDL via enhanced hepatic clearance \[[@CR96]\]. The binding site of PCSK9 to the LDLRs was identified as the first epidermal growth factor-like repeat (EGF-A) in the EGF homology domain \[[@CR97]\]. PCSK9 binding to EGF-A appears to interfere with a conformational change required for receptor turnover, effectively shunting LDLRs from recycling to degradation fates.

Intraperitoneal administration of a murine-specific PCSK9 2′-MOE-modified ASO (ISIS 394814) to high fat-fed mice for 6 weeks reduced total cholesterol and LDL-C by −53 and −38 %, respectively, and produced a twofold increase in liver LDLR protein concentrations \[[@CR100]\]. Further, ISIS 394814 produced hepatic PCSK9 mRNA reductions of 92 % vs. saline after 6 weeks of treatment. To demonstrate that the LDL lowering produced by the PCSK9 ASO required functional LDL receptors, studies were also performed in *Ldlr*-deficient mice treated with ASO for 6 weeks at 50 mg/kg/week. As anticipated, in mice genetically lacking LDLR, no reduction in plasma lipid levels was observed. Based upon these positive effects in multiple mouse models, high-density screens were performed in human hepatoma cell lines to identify an optimal human PCSK9 ASO inhibitor. A subsequent Phase I clinical trial was conducted evaluating a 2′-MOE-modified human PCSK9 ASO (BMS-844421) but was terminated by Bristol-Myers Squibb in January 2011 \[[@CR101]\].

A similar lipid-lowering profile was also observed testing a LNA-modified ASO after IV administration in mice \[[@CR102]\]. Based upon those compelling preclinical findings with the (LNA) ASO, Santaris Pharma A/S initiated a Phase I clinical trial in May 2011 evaluating SPC5001, an optimized human PCSK9 compound \[[@CR103]\]. This trial was also terminated in November 2011. A recent publication revealed that SPC5001 produced acute renal injury in a single subject following three weekly doses of 5 mg/kg on days 1, 8, and 15 \[[@CR104]\].

Researchers at Alnylam developed active, cross-species siRNAs capable of targeting PCSK9 expression in rodents, non-human primates, and humans. For in vivo studies, PCSK9 and control siRNAs were formulated in lipidoid nanoparticles. Liver-specific siRNA silencing of PCSK9 in mice and rats reduced PCSK9 mRNA levels by 50--70 % \[[@CR105]\] with a concomitant 60 % reduction in plasma total cholesterol concentrations. In PCSK9 transgenic mice, siRNAs suppressed the human PCSK9 transcript by \>70 % while significantly reduced PCSK9 plasma protein levels. In a non-human primate study, a single dose of the PCSK9 siRNA targeting resulted in a rapid lowering of plasma PCSK9, apoB, and LDL, without affecting HDL or TG levels.

Alnylam initiated a randomized, single-blind, placebo-controlled, single-ascending-dose Phase I study in healthy volunteers with elevated LDL-C \> 3 mmol/L (116 mg/dL) in September 2011 \[[@CR106]\]. As a monotherapy, ALN-PCS02 resulted in statistically meaningful and durable reductions of plasma PCSK9 of up to 84 % and lowering of LDL-C of up to 50 %. Results following a single dose of ALN-PCS support a once-monthly dosing regimen. ALN-PCS02 was shown to be safe and well tolerated in this study, and there were no serious adverse events. An additional Phase I trial is underway to further evaluate ALN-PCS02, an intravenously administered siRNA, vs. ALN-PCSsc, a subcutaneously administered alternate formulation.

Currently the most advanced PCSK9 clinical inhibitors are humanized Mab. Both Regeneron (REGN727) and Amgen (AMG145) are conducting multiple Phase II/III trials where primary outcomes will be determined in tens of thousands of dyslipidemic subjects \[[@CR9], [@CR94]\]. Results obtained from these ongoing clinical trials will ultimately determine the validity and safety of targeting PCSK9 as a lipid-lowering therapeutic approach.

ISIS-APOA~Rx~ {#Sec6}
=============

Lp(a) is a complex lipoprotein particle found in human plasma. Lp(a) consists of a LDL-like particle with apolipoprotein(a) (apo(a)) bound to the apoB protein via a disulfide bond. The apo(a) protein shows a high degree of homology to plasminogen at both the nucleotide and the amino acid level \[[@CR107]\]. However, in humans, the apo(a) gene transcript is much larger due to a repetitive kringle IV domain in the *LPA* gene. The majority of apo(a) mRNA is expressed in the liver, with minor amounts present in the testis, brain, adrenals, lung, and pituitary. Elevated Lp(a) levels are an independent risk factor for the development of cardiovascular disease, peripheral vascular, and cerebrovascular disease \[[@CR108], [@CR109]\]. Recently a genome-wide association study identified a SNP in the *LPA* locus that was significantly associated with aortic valve calcification across several ethnic groups \[[@CR110]\]. While extensive epidemiological evidence indicates that elevated plasma Lp(a) levels are pro-atherogenic \[[@CR111]\], the molecular mechanisms by which it contributes to the atherosclerotic process remain enigmatic. There is evidence that apo(a) may impair fibrinolysis of thrombosis, accelerate macrophage foam cell formation \[[@CR112]\], and act as a sink for oxidized phospholipids \[[@CR113]\].

Due to the expanding evidence indicating that Lp(a) contributes to CAD, a human apo(a)-specific ASO was developed and characterized in three human *LPA* transgenic mouse models: (1) mice expressing a human *LPA* construct (8K-*LPA* mouse) and (2) mice expressing human *APOB* and the human *LPA* construct (8K-*LPA* and transgenic mice expressing the natural human apo(a) gene in a yeast artificial chromosome (12K-*LPA*)) \[[@CR114]\]. Mice treated for 4 weeks showed significant reductions in hepatic apo(a) mRNA expression, with the ASO showing greater efficacy in the 12K-*LPA* (87 % reduction compared to saline) relative to the 8K-*LPA* and in the 8K-*LPA* (52 % reduction). In the 12K-*LPA* mouse, apo(a) ASO treatment significantly reduced plasma apo(a) protein levels (11,060 ± 7,137 vs. 76,983 ± 14,598 RLU at baseline) and OxPL/m-apoB (9,965 ± 907 vs. 28,003 ± 2,573 RLU at baseline). These encouraging preclinical results provided the impetus to initiate a Phase I trial in March 2013 to assess the efficacy and safety of the APOA~Rx~ in healthy human volunteers. Results from these ongoing trials will define the potential therapeutic benefit of reducing plasma apo(a) levels in dyslipidemic patients.

Summary {#Sec7}
=======

After more than 30 years of basic research and a significant investment in nucleic acid-based medicinal chemistry optimization, antisense technology has emerged as a third therapeutic platform, distinct from small molecule and protein-based approaches, for the treatment of a wide variety of disease indications. Extensive preclinical research and clinical experience with second-generation ASOs have demonstrated that these drugs are safe and efficacious agents that can selectively reduce the expression of a wide variety of disease-associated proteins. Further, the inherent specificity of the ASO-mediated mRNA termination mechanism allows for precise isoform targeting, which has proven difficult with other drug classes. Mipomersen, the first systemic antisense drug approved by the FDA for the treatment of hypercholesterolemia in HoFH patients, represents the first of many other therapeutic opportunities in clinical development. In addition to dyslipidemia indications, ASOs targeting inflammation, cancer, coagulation, neurological diseases, metabolic syndrome, rare genetic disease, and splicing disorders are currently advancing in the clinic.
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